Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr 20;4(5):100468.
doi: 10.1016/j.xkme.2022.100468. eCollection 2022 May.

Should We Use Dialyzable β-Blockers in Hemodialysis?

Affiliations
Editorial

Should We Use Dialyzable β-Blockers in Hemodialysis?

Panagiotis I Georgianos et al. Kidney Med. .
No abstract available

PubMed Disclaimer

References

    1. Lea-Henry T.N., Carland J.E., Stocker S.L., Sevastos J., Roberts D.M. Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol. 2018;13(7):1085–1095. - PMC - PubMed
    1. Frankenfield D.L., Weinhandl E.D., Powers C.A., Howell B.L., Herzog C.A., St Peter W.L. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D. Am J Kidney Dis. 2012;59(5):670–681. - PubMed
    1. Georgianos P.I., Agarwal R. Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. Nat Rev Nephrol. 2016;12(10):636–647. - PubMed
    1. Roberts D.M., Sevastos J., Carland J.E., Stocker S.L., Lea-Henry T.N. Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens. Clin J Am Soc Nephrol. 2018;13(8):1254–1263. - PMC - PubMed
    1. Tella A., Vang W., Ikeri E., et al. β-blocker use and cardiovascular outcomes in hemodialysis: a systematic review. Kidney Med. 2022 - PMC - PubMed

Publication types

LinkOut - more resources